Nivolumab,Ipilimumab,celecoxib
BMS
['ipi+', 'congrat', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'nivo']
amazing results for ipi+nivo with 95% response rate in dmmr crc patients #esmo22 #immunotherapy #coloncancer
congratulation 
The company is a leading provider of an AI-powered precision oncology platform transforming biomarker discovery and treatment decisions.